Favezelimab
As of the edition of 20 October 2026, Favezelimab is an antibody: in active development; acts on LAG3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 14, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Pregnancy and women's health; Urinary and reproductive; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LAG3 | Lymphocyte activation gene 3 protein | P18627 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 10 | 5 | 3 | 2 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2016 to now |